Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Therapeutic Vaccination With Escalating Doses of Theravac®, a Proteinic Vector Targeting Dendritic Cells Coupled to a Melanoma Antigen, in Patients With Advanced Metastatic Melanoma.

NCT01331915 is registered in ClinicalTrials.gov with Cliniques universitaires Saint-Luc- Université Catholique de Louvain as lead sponsor.

NCT NCT01331915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01331915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Therapeutic Vaccination With Escalating Doses of Theravac®, a Proteinic Vector Targeting Dendritic Cells Coupled to a Melanoma Antigen, in Patients With Advanced Metastatic Melanoma.
Lead sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2010
Completion date
Not reported
Enrollment
23 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma